CAC
STLNW

Cowen and Company’s Starling Oncology Warrant STLNW Stock Holding History

Cowen and Company’s Portfolio STLNW Stock Details STLNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-86,726
Closed -$1.73K – 293
2024
Q3 		$1.73K Sell
86,726
-400
-0.5% -$8 ﹤0.01% 584
2024
Q2 		$2.29K Buy
87,126
+400
+0.5% +$31 ﹤0.01% 566
2024
Q1 		$17.3K Sell
86,726
-34,874
-29% -$7.96K ﹤0.01% 455
2023
Q4 		$24.3K Buy
121,600
+400
+0.3% +$63 ﹤0.01% 327
2023
Q3 		$11.1K Buy
121,200
+600
+0.5% +$49 ﹤0.01% 445
2023
Q2 		$3.36K Buy
120,600
+300
+0.2% +$17 ﹤0.01% 499
2023
Q1 		$7.83K Buy
120,300
+200
+0.2% +$25 ﹤0.01% 413
2022
Q4 		$13.2K Buy
+120,100
New +$39.2K ﹤0.01% 377
2021
Q2 		– Sell
-16,000
Closed -$22K – 696
2021
Q1 		$22K Buy
16,000
+5,710
+55% +$10.6K ﹤0.01% 447
2020
Q4 		$20K Sell
10,290
-751
-7% -$1.29K ﹤0.01% 322
2020
Q3 		$18K Buy
+11,041
New +$18.1K ﹤0.01% 361

Other funds holding STLNW

LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $62.7B AUM 29.77% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
AGM
Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return
TCM
Tenor Capital Management New York $7.09B AUM 3.55% 1-Year Est. Return
FL
FreeGulliver LLC New Orleans, Louisiana $284M AUM 24.22% 1-Year Est. Return

Cowen and Company's STLNW Position: Q4 2024 in Review

Cowen and Company sold out of Starling Oncology Warrant (STLNW) in Q4 2024, closing a stake of 86,726 shares — an estimated $1.73K sold.

Cowen and Company first reported a position in STLNW in Q3 2020 and held it in 11 quarters. The position peaked at $24.3K in Q4 2023. 14 funds tracked by Wall St. Rank hold STLNW as of Q4 2024.

  • Cowen and Company reported no remaining Starling Oncology Warrant position as of Q4 2024 after selling out during the quarter.
  • Cowen and Company sold 86,726 Starling Oncology Warrant shares in Q4 2024, an estimated $1.73K.
  • Cowen and Company first reported a position in Starling Oncology Warrant in Q3 2020 and held it in 11 quarters.
  • Cowen and Company's Starling Oncology Warrant position peaked at $24.3K in Q4 2023.
  • 14 funds tracked by Wall St. Rank held Starling Oncology Warrant as of Q4 2024.

Based on Cowen and Company's 13F filing for Q4 2024.